Browse Menu >>

Browse Subjects >>

Biomedical & Life Sciences

Business & Economics

Chemistry & Materials Science

Computer Science & Communications

Earth & Environmental Sciences

Engineering

Medicine & Healthcare

Physics & Mathematics

Social Sciences & Humanities

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

T. Ben-Yedidia, H. Marcus, Y. Reisner and R. Arnon, “Intranasal Administration of Peptide Vaccine Protects Human/Mouse Radiation Chimera from Influenza Infection,” International Immunology, Vol. 11, No. 7, 1999, pp. 1043-1051. doi:10.1093/intimm/11.7.1043

has been cited by the following article:

  • TITLE: Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer

    AUTHORS: Nathalie Machluf, Ruth Arnon

    KEYWORDS: Breast Cancer; Flagella; Vaccine; Immunization; Prophylactic; MUC 1; Transgenic Mice; Tumor Growth

    JOURNAL NAME: World Journal of Vaccines, Vol.2 No.3, August 3, 2012

    ABSTRACT: MUC1, a tumor-associated antigen overexpressed in many carcinomas, represents a candidate of choice for cancer immunotherapy. Flagella-based MUC1 vaccines were tested in therapeutic setting in two aggressive breast cancer models, comprising the implantation of the 4T1-MUC1 cell line in either Balb/c, or Human MUC1 transgenic mice in which spontaneous metastases occurs. Recombinant flagella carrying only 7 amino acid of MUC1 elicited therapeutic activity, affecting both the growth of established growing tumors and the number of metastases. Higher therapeutic activity was achieved with an additional recombinant flagella designed with the SYFPEITHI algorithm. The vaccines triggered a Th1 response against MUC1 with no evident autoimmune response towards healthy MUC1-expressing tissues. Recombinant flagella carrying a 25-residue fragment of MUC1, induced the most effective response, as evidenced by a significant reduction of both the size and growth rate of the tumor as well as by the lower number of metastases, and expanding life span of vaccinated mice.